HopeCare Global Inc
Know the signs

Why There Is No Routine Ovarian Cancer Screening Test, and What to Do Instead

7 min readJune 21, 2026

If you've ever asked your doctor, "Can I get tested for ovarian cancer?", and walked away confused by the answer, you are not alone. Many women expect there's a simple yearly test, like a Pap smear or a mammogram, that can catch ovarian cancer early. The honest, real-talk answer is that for most women, there isn't one. Not yet.

That can feel scary. But "no routine test" does not mean "nothing you can do." It means the path to protecting yourself looks a little different. This article explains why there is no routine ovarian cancer screening test for women at average risk, what the research actually shows, and the practical steps that genuinely help with early detection.

What "screening" really means

Screening means testing people who feel completely fine, no symptoms at all, to catch a disease early. A good screening test has to do two things well: find cancers that matter, and avoid causing harm to healthy people.

For ovarian cancer, the tests we have today don't clear that bar for average-risk women. That's the heart of the issue.

Why there is no routine ovarian cancer screening test

Researchers have studied this carefully. The two main tools people ask about are:

  • The CA-125 blood test, which measures a protein that can be higher in some ovarian cancers.
  • Transvaginal ultrasound (TVUS), an imaging test that looks at the ovaries.

On paper these sound promising. In practice, they fall short as screening tools for women who have no symptoms and no known high risk. Here's why.

The tests miss cancers and raise false alarms

CA-125 is not reliable for early detection. Only about half of women with early-stage ovarian cancer have a raised CA-125 level, so a normal result can give false reassurance. At the same time, many common, non-cancerous conditions, like endometriosis, fibroids, or pelvic inflammatory disease, can raise CA-125, creating false alarms. (American Cancer Society)

Ultrasound has its own limits. It can spot a mass on an ovary, but it usually can't tell whether that mass is cancer or harmless. In fact, most masses found this way are not cancer. (American Cancer Society)

Screening healthy women didn't save lives, and caused harm

This is the part that surprises people. Large, high-quality studies looked at whether screening average-risk women with CA-125 and ultrasound lowered the number of deaths from ovarian cancer. It didn't. (U.S. Preventive Services Task Force)

Worse, the screening led to harm. Because the tests produce so many false positives, healthy women ended up having surgery, including operations to remove ovaries, for what turned out to be benign findings. After weighing this evidence, the U.S. Preventive Services Task Force (USPSTF) concluded that the harms of screening average-risk women outweigh the benefits. It recommends against routine ovarian cancer screening for women who have no symptoms and are not at high risk. (U.S. Preventive Services Task Force)

No major medical organization currently recommends routine screening for average-risk women.

Why early detection still matters so much

This is the hard truth that makes the screening gap sting. Ovarian cancer is often found late, because the early symptoms are vague and easy to mistake for everyday issues. Most women are diagnosed at an advanced stage, when the cancer is harder to treat. (American Cancer Society)

A woman's lifetime risk of developing ovarian cancer is roughly 1 in 91, and the lifetime chance of dying from it is about 1 in 143. (American Cancer Society) It is not the most common cancer, but it is a serious one, and catching it earlier gives treatment a better chance to work.

So if there's no test, what can you do? Quite a lot, actually.

What to do instead: know your body and your risk

1. Learn the symptoms, and take them seriously

Right now, the most powerful early-detection tool is you paying attention to your own body. Ovarian cancer can cause symptoms; the problem is they're easy to brush off. Watch for these, especially when they are new for you, frequent (happening most days), and last more than a couple of weeks:

  • Bloating that doesn't go away
  • Pelvic or belly pain or pressure
  • Feeling full quickly when eating, or trouble eating
  • Needing to urinate urgently or often

These symptoms are far more often caused by something other than cancer. But if they're new for you and persistent, that's your cue to see a clinician, not to panic, and not to wait it out. (Centers for Disease Control and Prevention)

2. Know your family history and risk factors

Recommendations are different for women at high risk. You may be at higher risk if you have:

  • A BRCA1 or BRCA2 gene change
  • A strong family history of ovarian, breast, or related cancers
  • Certain inherited conditions, such as Lynch syndrome

For high-risk women, doctors may recommend genetic counseling, closer monitoring, or other prevention options. This is exactly why knowing your family's health story matters, it can change the plan your doctor builds with you. (U.S. Preventive Services Task Force)

3. Keep up with regular gynecologic care

A routine pelvic exam is not a reliable screening test for ovarian cancer, and a Pap smear does not detect it. But staying connected to a clinician you trust means you have somewhere to bring concerns early, and a provider who knows your history. That relationship is part of early detection.

4. Speak up, and ask again if you're brushed off

If your symptoms are persistent and you don't feel heard, it is okay to advocate for yourself. Ask directly whether your symptoms could be related to your ovaries, and whether an exam, ultrasound, or CA-125 test makes sense for your situation. (Note: these tests are used to evaluate symptoms in someone who already has them, that is different from screening healthy people who feel fine.)

A word on equity: why this matters even more for some women

Not everyone faces ovarian cancer on a level playing field. Research shows Black women have lower survival than white women, driven in large part by disparities in timely diagnosis, access to specialists, and guideline-recommended treatment. Tellingly, when Black and white women have the same stage of disease and receive similar treatment, that survival gap largely disappears, a sign that the problem lies in access to care, not in the women themselves. (American College of Obstetricians and Gynecologists / CDC evidence review)

When there's no screening test to fall back on, symptom awareness and access to care become the great equalizers, or, when they're missing, the great dividers. That's why education that reaches every community, in plain and culturally grounded language, is a matter of life and health.

Key takeaways

  • There is no routine ovarian cancer screening test recommended for women at average risk, because the available tests (CA-125 and ultrasound) miss cancers, cause false alarms, and haven't been shown to save lives in healthy women.
  • Routine screening can cause real harm, including unnecessary surgery, which is why the USPSTF recommends against it for average-risk, symptom-free women.
  • Most ovarian cancers are found at a later stage, so symptom awareness is currently the best early-detection tool.
  • Watch for bloating, pelvic or belly pain, feeling full quickly, and urinary changes that are new, frequent, and persistent, and get them checked.
  • High-risk women are different: know your family history, and ask about genetic counseling and closer monitoring.
  • Disparities in access mean education and timely care matter especially for women historically left out of the conversation.

You don't have to navigate this alone

If anything here sounds familiar, the most caring thing you can do is talk with a clinician, not to scare yourself, but to get clear answers about your body and your risk. You deserve to be heard.

At HopeCare Global, this is the heart of our work: helping women recognize the signs early, understand their risk in plain language, and find their way to the care and support they need, including women too often left out of the conversation. Early detection, honest education, and standing with patients and families is our mission, every day.

---

Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. It does not provide individualized medical advice. Always talk with a qualified healthcare provider about your specific symptoms, risk factors, and care decisions. If you have a medical emergency, seek care immediately.

Sources

  • U.S. Preventive Services Task Force (USPSTF), The USPSTF recommends against screening for ovarian cancer in asymptomatic women not at high risk (grade D); screening did not reduce ovarian cancer mortality and caused harms including unnecessary surgery.
  • American Cancer Society, CA-125 is raised in only about half of early-stage ovarian cancers and can be elevated by benign conditions; transvaginal ultrasound finds masses but cannot distinguish cancer from benign, and most masses found in screening are not cancer. No major organization recommends these tests for routine screening of average-risk women.
  • American Cancer Society, A woman's lifetime risk of developing ovarian cancer is about 1 in 91, and lifetime risk of dying from it is about 1 in 143 (current ACS figures, 2026 estimates).
  • American Cancer Society (SEER-based survival/stage data), The majority of women with ovarian cancer are diagnosed at an advanced stage, when survival is lower (roughly three-quarters at stage III/IV).
  • Centers for Disease Control and Prevention (CDC), Common ovarian cancer symptoms to evaluate include bloating, pelvic/abdominal pain or pressure, feeling full quickly or difficulty eating, and urinary urgency/frequency, concerning when new, persistent, and a change from normal (occurring frequently, e.g. more than ~12 times per month).
  • American College of Obstetricians and Gynecologists / CDC-supported evidence review (Obstetrics & Gynecology, 2023), Black women experience worse ovarian cancer survival than white women, driven substantially by disparities in late-stage diagnosis, access to care, and receipt of guideline-concordant treatment; the survival gap largely disappears among patients with the same stage and similar treatment.